EME and AprilBio Launch Joint Development of Next-Generation VHH Antibody Therapeutics
Epsilon Molecular Engineering, Inc. (Head Office: Saitama, Japan; CEO: Naoto Nemoto, “EME”) has entered into a strategic partnership with AprilBio Co., Ltd. (397030.KQ; South Korea, “AprilBio”) to jointly develop next-generation VHH antibody therapeutics. The two companies have signed a Memorandum of Understanding (MOU) aimed at joint research, development, and global commercialization, leveraging each party’s core platform technologies.
Click here for the full article.
This agreement represents a significant milestone for EME in expanding its antibody platform technology to the global market. Through this partnership, EME aims to demonstrate the innovation of its platform, accelerate the development of novel therapeutics, and broaden the reach of next-generation antibody-based treatments beyond Japan.
【Contact us】
Epsilon Molecular Engineering, Inc.
Business Development Department
E-mail : biz_dev@epsilon-mol.co.jp
